Evidence map›Paper›PMID 38699723›Full record

ArticleHeliyon2024

Novel artemisinin derivative P31 inhibits VEGF-induced corneal neovascularization through AKT and ERK1/2 pathways.

Wen Ding, Yingxue Su, Jianshan Mo, Danyuan Sun, Chen Cao, Xiaolei Zhang, Yandong Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wen DingState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Engineering Research Center for Ophthalmic Drug Creation and Evaluation, Guangzhou, 510060, China.
Yingxue SuState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Engineering Research Center for Ophthalmic Drug Creation and Evaluation, Guangzhou, 510060, China.
Jianshan MoSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Danyuan SunSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Chen CaoState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Engineering Research Center for Ophthalmic Drug Creation and Evaluation, Guangzhou, 510060, China.
Xiaolei ZhangSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Yandong WangState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Engineering Research Center for Ophthalmic Drug Creation and Evaluation, Guangzhou, 510060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Corneal neovascularization (CoNV)is a major cause of blindness in many ocular diseases. Substantial evidence indicates that vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of corneal neovascularization. Previous evidence showed that artemisinin may inhibit angiogenesis through down regulation of the VEGF receptors. We designed and synthesized artemisinin derivatives, and validated their inhibitory effect on neovascularization in cell and animal models, and explored the mechanisms by which they exert an inhibitory effect on CoNV. Among these derivatives, P31 demonstrated significant anti-angiogenic effects

Identifiers

PMID38699723
PMCPMC11063438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.